Nowadays, treatments targeting the aberrant vascular endothelial growth factor/receptor (VEGF/VEGFR) pathway and/or immune checkpoint inhibitors are among the main and most effective therapy for ccRCC. Here, KDR is linked to nonpapillary renal cell carcinoma.